Proposal to list medical devices supplied by McLaren Medical Distributors Limited
PHARMAC is seeking feedback on a proposal to list a range of medical devices supplied by McLaren Medical Distributors Limited.
What we’re proposing
PHARMAC is seeking feedback on a proposal to list a range of medical devices supplied by McLaren Medical Distributors Limited (“McLaren Medical”) in Part III of Section H of the Pharmaceutical Schedule from 1 April 2021.
Consultation closes at 4pm Friday 19 February 2021 and feedback can be emailed to email@example.com.
What would the effect be?
From 1 April 2021 McLaren Medical’s range of medical devices in the respiratory equipment and consumables category would be listed in Part III of Section H of the Pharmaceutical Schedule under a proposed national agreement for all DHB hospitals to purchase under, subject to consultation and approval by PHARMAC’s Board or delegate (the “Agreement”).
The Agreement would not be for sole supply. DHBs would be able to continue to purchase other suppliers’ brands of respiratory equipment and consumables.
The Agreement would supersede any existing DHB contracts with McLaren Medical for the medical devices included in the Agreement. Any medical devices listed in the Agreement, and purchased by a DHB, would be at the terms and conditions, including price, stated in the Agreement, effective from the date of the listing on the Pharmaceutical Schedule.
McLaren Medical would provide appropriate educational services, that would be tailored to the individual needs of the DHBs, in formats and at times as required by the DHBs.
Pricing for the devices in this Agreement, subject to any prior termination of the Agreement, would not be increased without prior consultation and approval by PHARMAC.
Who we think will be interested
- Suppliers and wholesalers
- Clinical and non-clinical DHB staff:
- Clinical/biomedical engineers
- Anaesthetists and anaesthetic technicians
- Clinical staff involved with airway management and emergency respiratory resuscitation
- Respiratory clinicians
- Respiratory therapists
- Pulmonary function specialists
- Pulmonary rehabilitation specialists
- Procurement and supply chain personnel
About respiratory equipment and consumables
Respiratory care is a health specialty involving the diagnosis, assessment, treatment and management of patients with deficiencies and abnormalities of the cardiopulmonary system.
The respiratory equipment and consumables category includes oxygen delivery consumables and accessories, aerosol delivery devices and associated consumables, non-powered humidifiers (passive and bubble) and associated tubing and consumables, laryngectomy and tracheostomy consumables, spirometers and respiratory muscle trainers and associated consumables, breathing filters, powered and non-powered respiratory suction devices and associated consumables, ventilator circuits and associated consumables and flow meters.
Why we’re proposing this
In 2017 PHARMAC issued a Request for Proposals (“RFP”) for:
The RFPs were for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
PHARMAC has been working with suppliers to seek provisional agreements and this proposal is the latest to arise from this process. We expect to consult on further proposed agreements in this category over the coming months.
Details about our proposal
PHARMAC has entered into a provisional agreement with McLaren Medical for their range of Respiratory Equipment and Consumables.
The proposal would result in Pharmaceutical Schedule listings for 10 respiratory equipment and consumable products. The proposed respiratory equipment and consumable products are from the Filter, Spirette, Easy-onPC, EasyOne Air, Neumofilt, Neumoclip and Flowtube brands.
Further information, including pricing and contractual details, has been provided to DHB Procurement personnel. Clinicians interested in further detail on what this proposal means for their DHB should engage with their Procurement teams.
To provide feedback
Send us an email: firstname.lastname@example.org by 4pm Friday 19 February 2021.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.